Molecular approaches to chemo-radiotherapy

European Journal of Cancer

Volumn 38, Issue 2, 2002, Pages 231-239

  Marples, B ^a   Greco, O ^a   Joiner, M C ^a   Scott, S D ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

CArG elements; GDEPT; Gene therapy; Hypoxia; Promoters; Radiation

Indexed keywords

CARRIER PROTEIN; GANCICLOVIR; HYBRID PROTEIN; PRODRUG; THYMIDINE KINASE;

ARTICLE; BACTERIOPHAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER TISSUE; CELL KILLING; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HYPOXEMIA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; RADIATION RESPONSE; TARGET ORGAN; TISSUE SPECIFICITY; TUMOR CELL LINE; VIRUS GENE;

ANOXIA; COMBINED MODALITY THERAPY; GENE EXPRESSION; GENE THERAPY; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); RADIOTHERAPY; TRANSFECTION;

EID: 0036166703     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00367-7     Document Type: Article

References (83)

1. Therapeutic targets in radiotherapy
2. Cancer gene therapy: Hard lessons and new courses
3. Gene therapy: Designer promoters for tumour targeting
4. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives
5. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents
6. Approaches to enhance cancer radiotherapy employing gene transfer methods
7. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft
8. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells
9. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter
10. WAF1, a potential mediator of p53 tumor suppression
11. Identification and characterization of X-ray-induced proteins in human cells
12. Mammalian genes induced by radiation; activation of genes associated with growth control
13. Radiation induction of immediate early genes: Effectors of the radiation-stress response
14. Immediate x-ray-inducible responses from mammalian-cells
15. Induction of stress genes by low doses of gamma rays
16. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD4′5 is defective in ataxia-telangiectasia
17. Transcriptional activation and repression by Fos are independent functions: The C terminus represses immediate-early gene expression via CArG elements
18. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature
19. Spatial and temporal control of gene therapy using ionizing radiation
20. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir
21. Induction of the suicide HSV-TK gene by activation of the Egr-1 promoter with radioisotopes
22. Ionizing radiation activates transcription of the EGR1 gene via CArG elements
23. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation
24. 5′ flanking sequence and genomic structure of Egr-1, a murine mitogen inducible zinc finger encoding gene
25. 5′ upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8
26. DNA binding site of the growth factor-inducible protein Zif268
27. Functional serum response elements upstream of the growth factor-inducible gene zif268
28. Development of synthetic promoters for radiation-mediated gene therapy
29. Aequorea green fluorescent protein analysis by flow cytometry
30. Rapid generation and flow cytometric analysis of stable GFP-expressing cells
31. A radiation-controlled molecular switch for use in gene therapy of cancer
32. In situ use of suicide genes for cancer therapy
33. Prodrug-activating systems in suicide gene therapy
34. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination
35. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect
36. Development of a novel enzyme/prodrug combination for gene therapy of cancer: Horseradish peroxidase/indole-3-acetic acid
37. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents
38. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene
39. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo
40. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts
41. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
42. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization
43. The role of the bystander effect in suicide gene therapy
44. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
45. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo
46. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo
47. Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect"
48. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene
49. Bystander tumoricidal effect in the treatment of experimental brain tumors
50. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
51. Intercellular trafficking and protein delivery by a herpesvirus structural protein
52. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines
53. Intercellular delivery of functional p53 by the herpesvirus protein VP22
54. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
55. Can VP22 resurrect gene therapy?
56. Comment on the use of the cre/loxP recombinase system for gene therapy vectors
57. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
58. Enhancement of radiotherapy by hyperthermia-regulated gene therapy
59. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
60. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome
61. Oxygenation predicts radiation response and survival in patients with cervix cancer
62. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
63. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy
64. Hypoxic cervical cancers with low apoptotic index are highly aggressive
65. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
66. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix
67. Modulation of c-Myc activity and apoptosis in vivo
68. Targeting gene expression to hypoxic tumor cells
69. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
70. Development of a hypoxia-responsive vector for tumor-specific gene therapy
71. Increasing specificity of anti-tumor therapy: Cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters
72. The use of radiation-induced bacterial promoters in anaerobic conditions: A means to control gene expression in clostridium-mediated therapy for cancer
73. Microenvironmental control of gene expression: Implications for tumor angiogenesis, progression, and metastasis
74. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target
75. Oxygen(es) and the hypoxia-inducible factor-1
76. Hypoxia response elements
77. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
78. Can gene therapy overcome the problem of hypoxia in radiotherapy?
79. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine
80. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma
81. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: Effect on clonogenicity in both two-and three-dimensional models
82. Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy
83. Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation